Blood Res 2017; 52(3):
Published online September 25, 2017
https://doi.org/10.5045/br.2017.52.3.193
© The Korean Society of Hematology
1Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
3Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
4Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Correspondence to : Sun-Hee Kim, M.D., Ph.D. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. sunnyhk@skku.edu
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) accounts for 5?10% of DLBCL cases and has poor patient outcomes. However, most studies on CD5+ DLBCL were performed in Japanese patients and only few data are available for Korean population. In this study, we investigated the clinical characteristics and prognostic impact of CD5 expression in Korean patients with bone marrow (BM) involvement of DLBCL.
Patients who were initially diagnosed with BM involvement of
Among a total of 57 patients, the number of patients with CD5+ and CD5? DLBCL were 13 and 44, respectively. Clinical and laboratory features of CD5+ DLBCL were not significantly different from those of CD5? DLBCL. The 3-year overall survival (OS) rates for CD5+ and CD5? DLBCL were 20.2% and 59.0%, respectively (
CD5+ DLBCL with BM involvement showed an inferior survival tendency compared to CD5? DLBCL, and thorough evaluation of CD5 expression might be helpful to predict the prognosis of patients with DLBCL.
Keywords Diffuse large B-cell lymphoma, CD5, Bone marrow, Korea
Blood Res 2017; 52(3): 193-199
Published online September 25, 2017 https://doi.org/10.5045/br.2017.52.3.193
Copyright © The Korean Society of Hematology.
Hyun-Young Kim1,2, Mi-Ae Jang3, Hee-Jin Kim1, Seok Jin Kim4, Won Seog Kim4, and Sun-Hee Kim1*
1Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
3Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
4Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Correspondence to:Sun-Hee Kim, M.D., Ph.D. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. sunnyhk@skku.edu
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) accounts for 5?10% of DLBCL cases and has poor patient outcomes. However, most studies on CD5+ DLBCL were performed in Japanese patients and only few data are available for Korean population. In this study, we investigated the clinical characteristics and prognostic impact of CD5 expression in Korean patients with bone marrow (BM) involvement of DLBCL.
Patients who were initially diagnosed with BM involvement of
Among a total of 57 patients, the number of patients with CD5+ and CD5? DLBCL were 13 and 44, respectively. Clinical and laboratory features of CD5+ DLBCL were not significantly different from those of CD5? DLBCL. The 3-year overall survival (OS) rates for CD5+ and CD5? DLBCL were 20.2% and 59.0%, respectively (
CD5+ DLBCL with BM involvement showed an inferior survival tendency compared to CD5? DLBCL, and thorough evaluation of CD5 expression might be helpful to predict the prognosis of patients with DLBCL.
Keywords: Diffuse large B-cell lymphoma, CD5, Bone marrow, Korea
Kaplan-Meier plots for the overall survival (OS) and progression-free survival (PFS) in
Kaplan-Meier plots for the (
Table 1 . Demographic and clinical characteristics of 57 patients with bone marrow involvement of
a)
Abbreviations: BM, bone marrow; CD5−, CD5 negative; CD5+, CD5 positive; CNS, central nervous system; GCB, germinal center B-cell like; IPI, international prognostic index; LDH, serum lactate dehydrogenase..
Ja Young Lee, Jae Hyun Kim, Jeong Hwan Shin, Hye Ran Kim, Jeong Nyeo Lee, Ki Hyang Kim, Won Sik Lee, Young Don Joo, Chang Hak Sohn, Chan-Hwan Kim
Korean J Hematol 2008; 43(1): 48-52Shuku Sato, Shun Tsunoda, Wataru Kamata, Tomiteru Togano and Yotaro Tamai
Blood Res 2025; 60():Youli Li, Yonghe Wu, Sufen Cao, Baohua Yu, Qunling Zhang, Zuguang Xia, Junning Cao, Fangfang Lv and Guang‑Liang Chen
Blood Res 2024; 59():
Kaplan-Meier plots for the overall survival (OS) and progression-free survival (PFS) in
Kaplan-Meier plots for the (